Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893348511> ?p ?o ?g. }
- W2893348511 endingPage "302" @default.
- W2893348511 startingPage "291" @default.
- W2893348511 abstract "Apert syndrome (AS), the most severe form of craniosynostosis, is caused by missense mutations including Pro253Arg(P253R) of fibroblast growth factor receptor 2 (FGFR2), which leads to enhanced FGF/FGFR2-signaling activity. Surgical correction of the deformed skull is the typical treatment for AS. Because of constant maldevelopment of sutures, the corrective surgery is often executed several times, resulting in increased patient challenge and complications. Biological therapies targeting the signaling of mutant FGFR2 allele, in combination with surgery, may bring better outcome. Here we screened and found a small interfering RNA (siRNA) specifically targeting the Fgfr2-P253R allele, and we revealed that it inhibited osteoblastic differentiation and matrix mineralization by reducing the signaling of ERK1/2 and P38 in cultured primary calvarial cells and calvarial explants from Apert mice (Fgfr2+/P253R). Furthermore, AAV9 carrying short hairpin RNA (shRNA) (AAV9-Fgfr2-shRNA) against mutant Fgfr2 was delivered to the skulls of AS mice. Results demonstrate that AAV9-Fgfr2-shRNA attenuated the premature closure of coronal suture and the decreased calvarial bone volume of AS mice. Our study provides a novel practical biological approach, which will, in combination with other therapies, including surgeries, help treat patients with AS while providing experimental clues for the biological therapies of other genetic skeletal diseases. Apert syndrome (AS), the most severe form of craniosynostosis, is caused by missense mutations including Pro253Arg(P253R) of fibroblast growth factor receptor 2 (FGFR2), which leads to enhanced FGF/FGFR2-signaling activity. Surgical correction of the deformed skull is the typical treatment for AS. Because of constant maldevelopment of sutures, the corrective surgery is often executed several times, resulting in increased patient challenge and complications. Biological therapies targeting the signaling of mutant FGFR2 allele, in combination with surgery, may bring better outcome. Here we screened and found a small interfering RNA (siRNA) specifically targeting the Fgfr2-P253R allele, and we revealed that it inhibited osteoblastic differentiation and matrix mineralization by reducing the signaling of ERK1/2 and P38 in cultured primary calvarial cells and calvarial explants from Apert mice (Fgfr2+/P253R). Furthermore, AAV9 carrying short hairpin RNA (shRNA) (AAV9-Fgfr2-shRNA) against mutant Fgfr2 was delivered to the skulls of AS mice. Results demonstrate that AAV9-Fgfr2-shRNA attenuated the premature closure of coronal suture and the decreased calvarial bone volume of AS mice. Our study provides a novel practical biological approach, which will, in combination with other therapies, including surgeries, help treat patients with AS while providing experimental clues for the biological therapies of other genetic skeletal diseases." @default.
- W2893348511 created "2018-10-05" @default.
- W2893348511 creator A5000677856 @default.
- W2893348511 creator A5011065863 @default.
- W2893348511 creator A5011616753 @default.
- W2893348511 creator A5014297196 @default.
- W2893348511 creator A5021385278 @default.
- W2893348511 creator A5022997397 @default.
- W2893348511 creator A5032669203 @default.
- W2893348511 creator A5038351060 @default.
- W2893348511 creator A5041762848 @default.
- W2893348511 creator A5044405188 @default.
- W2893348511 creator A5049317673 @default.
- W2893348511 creator A5050338926 @default.
- W2893348511 creator A5050911555 @default.
- W2893348511 creator A5054012489 @default.
- W2893348511 creator A5057655952 @default.
- W2893348511 creator A5060037355 @default.
- W2893348511 creator A5064523767 @default.
- W2893348511 creator A5065966149 @default.
- W2893348511 creator A5071068810 @default.
- W2893348511 creator A5079920320 @default.
- W2893348511 creator A5083070137 @default.
- W2893348511 creator A5083321020 @default.
- W2893348511 date "2018-12-01" @default.
- W2893348511 modified "2023-10-14" @default.
- W2893348511 title "Adeno-Associated Virus-Mediated RNAi against Mutant Alleles Attenuates Abnormal Calvarial Phenotypes in an Apert Syndrome Mouse Model" @default.
- W2893348511 cites W1732242198 @default.
- W2893348511 cites W1929611763 @default.
- W2893348511 cites W1964395993 @default.
- W2893348511 cites W1965963850 @default.
- W2893348511 cites W1968963646 @default.
- W2893348511 cites W1972895757 @default.
- W2893348511 cites W1983198126 @default.
- W2893348511 cites W1988458080 @default.
- W2893348511 cites W1995352016 @default.
- W2893348511 cites W1998689916 @default.
- W2893348511 cites W2003463719 @default.
- W2893348511 cites W2008289270 @default.
- W2893348511 cites W2009425793 @default.
- W2893348511 cites W2010843037 @default.
- W2893348511 cites W2035110063 @default.
- W2893348511 cites W2037852232 @default.
- W2893348511 cites W2044280612 @default.
- W2893348511 cites W2046072419 @default.
- W2893348511 cites W2047103966 @default.
- W2893348511 cites W2054567767 @default.
- W2893348511 cites W2060431635 @default.
- W2893348511 cites W2067732333 @default.
- W2893348511 cites W2078578654 @default.
- W2893348511 cites W2095509700 @default.
- W2893348511 cites W2099062342 @default.
- W2893348511 cites W2099999081 @default.
- W2893348511 cites W2100581989 @default.
- W2893348511 cites W2111096971 @default.
- W2893348511 cites W2113771280 @default.
- W2893348511 cites W2132354121 @default.
- W2893348511 cites W2132629764 @default.
- W2893348511 cites W2133171074 @default.
- W2893348511 cites W2136363425 @default.
- W2893348511 cites W2151995950 @default.
- W2893348511 cites W2152150200 @default.
- W2893348511 cites W2412159251 @default.
- W2893348511 cites W2563698118 @default.
- W2893348511 cites W2570415350 @default.
- W2893348511 cites W2625994551 @default.
- W2893348511 cites W2754867791 @default.
- W2893348511 cites W2769676409 @default.
- W2893348511 cites W4231119834 @default.
- W2893348511 doi "https://doi.org/10.1016/j.omtn.2018.09.012" @default.
- W2893348511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6197781" @default.
- W2893348511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30321816" @default.
- W2893348511 hasPublicationYear "2018" @default.
- W2893348511 type Work @default.
- W2893348511 sameAs 2893348511 @default.
- W2893348511 citedByCount "12" @default.
- W2893348511 countsByYear W28933485112019 @default.
- W2893348511 countsByYear W28933485112020 @default.
- W2893348511 countsByYear W28933485112021 @default.
- W2893348511 countsByYear W28933485112022 @default.
- W2893348511 countsByYear W28933485112023 @default.
- W2893348511 crossrefType "journal-article" @default.
- W2893348511 hasAuthorship W2893348511A5000677856 @default.
- W2893348511 hasAuthorship W2893348511A5011065863 @default.
- W2893348511 hasAuthorship W2893348511A5011616753 @default.
- W2893348511 hasAuthorship W2893348511A5014297196 @default.
- W2893348511 hasAuthorship W2893348511A5021385278 @default.
- W2893348511 hasAuthorship W2893348511A5022997397 @default.
- W2893348511 hasAuthorship W2893348511A5032669203 @default.
- W2893348511 hasAuthorship W2893348511A5038351060 @default.
- W2893348511 hasAuthorship W2893348511A5041762848 @default.
- W2893348511 hasAuthorship W2893348511A5044405188 @default.
- W2893348511 hasAuthorship W2893348511A5049317673 @default.
- W2893348511 hasAuthorship W2893348511A5050338926 @default.
- W2893348511 hasAuthorship W2893348511A5050911555 @default.
- W2893348511 hasAuthorship W2893348511A5054012489 @default.
- W2893348511 hasAuthorship W2893348511A5057655952 @default.
- W2893348511 hasAuthorship W2893348511A5060037355 @default.